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Oxidative stressa b s t r a c t
In response to lipopolysaccharide (LPS), tissue resident macrophages and recruited neutrophils produce
inﬂammatory mediators through activation of Toll-like receptor 4 (TLR4)/nuclear factor kappa B (NF-jB)
signaling pathway. These mediators include inﬂammatory cytokines and reactive oxygen species that, in
turn, sensitize nociceptors and lead to inﬂammatory pain. Vinpocetine is a nootropic drug widely used to
treat cognitive and neurovascular disorders, and more recently its anti-inﬂammatory properties through
inhibition of NF-jB activation have been described. In the present study, we used the intraplantar and
intraperitoneal LPS stimulus in mice to investigate the effects of vinpocetine pre-treatment (3, 10, or
30 mg/kg by gavage) in hyperalgesia, leukocyte recruitment, oxidative stress, and pro-inﬂammatory cyto-
kine production (TNF-a, IL-1b, and IL-33). LPS-induced NF-jB activation and cytokine production were
investigated using RAW 264.7 macrophage cell in vitro. Vinpocetine (30 mg/kg) signiﬁcantly reduces
hyperalgesia to mechanical and thermal stimuli, and myeloperoxidase (MPO) activity (a neutrophil mar-
ker) in the plantar paw skin, and also inhibits neutrophil and mononuclear cell recruitment, superoxide
anion and nitric oxide production, oxidative stress, and cytokine production (TNF-a, IL-1b and IL-33) in
the peritoneal cavity. At least in part, these effects seem to be mediated by direct effects of vinpocetine on
macrophages, since it inhibited the production of the same cytokines (TNF-a, IL-1b and IL-33) and the
NF-jB activation in LPS-stimulated RAW 264.7 macrophages. Our results suggest that vinpocetine repre-
sents an important therapeutic approach to treat inﬂammation and pain induced by a gram-negative bac-
terial component by targeting NF-jB activation and NF-jB-related cytokine production in macrophages.
 2015 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Infection by gram-negative bacteria provokes pain and reduces
life quality of patients [1–3]. Lipopolysaccharide (LPS) from
gram-negative bacteria, or endotoxin, is a prototypical ligand of
membrane-bound pattern recognition receptor (PRR) Toll-like
receptor 4 (TLR4) and the major constituent of gram-negative bac-
terial cell wall, covering up to 75% of its outer surface [4].
Neutrophil-derived molecules, and even some antibiotics such as
ceftazidime, induce bacterial lysis and, consequently, the release
of large amounts of LPS [5]. Thus, despite killing bacteria, bacteriallysis increases the inﬂammatory pain and leads to an additional
post infectious sequel [5]. In this sense, targeting LPS effects is of
great clinical importance.
The activation of TLR4 expressed by resident macrophages leads
to intracellular signaling pathways that culminate in the activation
of nuclear factor kappa B (NF-jB) and pro-inﬂammatory cytokines
production, including TNF-a, IL-1b and IL-33 [6,7]. These mediators
induce the recruitment of neutrophils that, in turn, produce reactive
oxygen species (ROS), such as superoxide anion and its derivatives
[8]. Both macrophage- and neutrophil-released cytokines and ROS
activate and sensitize (hyperalgesia) nociceptive neurons [9–15].
In this sense, compounds that present both anti-inﬂammatory and
analgesic activities are candidates to treat LPS-induced inﬂamma-
tion and pain, and the TLR4 activation by LPS injection is a useful
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compounds.
Ethyl apovincamine-22-oate is also known as vinpocetine, a
safe nootropic drug [16] that is widely used to treat cognitive
and cerebrovascular disorders, including cerebral infarction and
residual cerebral hemorrhage [17,18]. The treatment with vin-
pocetine showed to be safe and non-toxic even in long-term use
[19–21], and no signiﬁcant side effects related to the treatment
have been reported [18,20,22]. The therapeutic effects of vin-
pocetine are related to its high capacity to protect neuronal cells
from the cytotoxic effects of inﬂammation, oxidative stress [23–
26], and ion ﬂux [27,28]. In other tissues, vinpocetine decreased
the acute hepatic injury caused by CCl4 in rats [29], and was gastro-
protective in rats [30,31] in addition to the anti-inﬂammatory
activity also reported elsewhere [32,33].
Although vinpocetine exhibits selective inhibitory activity over
phosphodiesterase-1 (PDE-1) enzyme [34], its anti-inﬂammatory
effects seem to be PDE-1-independent. Vinpocetine inhibits
LPS-induced lung inﬂammation in mice by targeting NF-jB activa-
tion and, consequently, the production of NF-jB-related cytokines
TNF-a and IL-1b, as well as the recruitment of polymorphonuclear
cells [32]. Corroborating this mechanism of action, vinpocetine
exhibited anti-atherogenic effect through inhibition of NF-jB acti-
vation and the resulting production of inﬂammatory cytokines
(TNF-a and IL-6), reactive oxygen species, and other inﬂammatory
mediators in a PDE-1-independentmanner [33]. In amodel of endo-
toxemia, intraperitoneal administration of vinpocetine reduced hip-
pocampal expression of IL-1b and TNF-a after intraperitoneal
stimulus with LPS [35]. In fact, the analgesic activity of intraperi-
toneal treatment with vinpocetine was described in acetic
acid-induced visceral nociception, corroborating the possible use
of this compound in inﬂammatory pain conditions [36]. However,
it was not determined if similar analgesic and anti-inﬂammatory
effects could be obtained by oral treatment with vinpocetine in
LPS-induced pain. In this study, we used in vivo and in vitro
approaches to investigate the effects of vinpocetine in LPS-induced
inﬂammatory pain and leukocyte recruitment, and their relation
to oxidative stress, cytokine production, and NF-jB activation.2. Materials and methods
2.1. Drugs
Materials were obtained from the sources as follows: commer-
cial tablets of vinpocetine (Vicog, Marjan Indústria & Comércio
Ltda, São Paulo, Brazil), vinpocetine powder at >98% purity (Santa
Cruz Biotechnology, Dallas, Texas, USA), LPS from Escherichia coli
0111:B4 (Santa Cruz Biotechnology).
2.2. Animals
Male Swiss mice (25–30 g) from the Universidade Estadual de
Londrina, Paraná, Brazil, were used in this study. Mice were housed
in standard clear plastic cageswith free access to food andwater and
a light/dark cycle of 12–12 h at 21 C. All behavioral testingwas per-
formed between 9 a.m. and 5 p.m. in a temperature-controlled
(21 C) room. Animal care and handling procedures were approved
by the Ethics Committee of the Universidade Estadual de Londrina
(process number 13278.2011.3). All efforts were made to minimize
animals’ suffering and to reduce the number of animals used.
2.3. General experimental procedures
Mice received per oral (p.o.) treatment with vinpocetine (3, 10,
or 30 mg/kg, 100 lL) or vehicle (sterile saline, 100 lL) 1 h beforestimulus injection. Mechanical and thermal hyperalgesia were
evaluated 1–5 h after intraplantar (i.pl.) injection of LPS (200 ng
in 25 lL of sterile saline). Neutrophil recruitment to the plantar
paw skin was evaluated 5 h after LPS i.pl. injection (200 ng in
25 lL of sterile saline) by myeloperoxidase (MPO) activity assay.
For oxidative stress tests, samples of plantar paw skin were col-
lected 3 h after LPS i.pl. injection (peak of hyperalgesia). In the peri-
toneal cavity, leukocyte recruitment and cytokine production were
evaluated 2 and 6 h after i.p. injection with LPS (200 ng in 200 lL of
sterile saline).
Supernatants and cell lysates from RAW 264.7 cell cultures
were collected 6 h after LPS stimulus (1 lg/mL) and used to evalu-
ate cytokine levels (ELISA) and NF-jB activation by luciferase gene
reporter assay, respectively.
2.4. Mechanical hyperalgesia test
Mechanical hyperalgesia was measured by an electronic version
of von Frey ﬁlaments [37]. The test consisted of evoking a hind paw
reﬂex with a hand-held force transducer (electronic anesthesiome-
ter; Insight Equipamentos, Ribeirao Preto, SP, Brazil). After paw
withdrawal, the pressure intensity was recorded automatically,
and the values were an average of three measurements. Mice were
tested before (basal) and after stimulus injection. The results are
expressed as delta (D) withdrawal threshold (in g), calculated by
subtracting the basal mean measurements from the mean mea-
surements obtained at 1, 3, or 5 h after i.pl. stimulus with LPS.
2.5. Hot plate test
Mice were placed on a hot plate apparatus (Hot Plate HP-2002,
Insight Equipamentos, Ribeirao Preto, SP, Brazil) maintained at
55 C. The reaction time was scored when the animal jumped or
licked its paws. A maximum latency (cut-off) was set at 30 s to
avoid tissue damage [38,39].
2.6. Myeloperoxidase (MPO) activity
The neutrophil recruitment to the plantar paw skin was evalu-
ated by the MPO kinetic-colorimetric assay [40,41]. Samples were
homogenized using a tissue-tearor (Biospec) in ice-cold K2HPO4
buffer (400 lL, 50 mM, pH 6.0) containing HTAB (0.5% weight/vol-
ume), and the homogenates were centrifuged (16,100g 
2 min  4 C). The supernatants (30 lL) were mixed with K2HPO4
buffer (200 lL, 50 mM, pH 6.0) containing o-dianisidine dihy-
drochloride (0.0167%, w/v) and hydrogen peroxide (0.015%, v/v).
The absorbance was determined after 5 min at 450 nm
(Multiskan GO Microplate Spectrophotometer, Thermo Scientiﬁc,
Vantaa, Finland). The results of MPO activity are expressed as the
number of neutrophils per mg of tissue by using a standard curve
of neutrophils (196–400,000 cells). Neutrophils were harvested
from peritoneal cavity 6 h after i.p. stimulus with thiglycolate
broth (1 mL, 5%, Becton Dickinson, MD, USA). The number of neu-
trophils was determined by total counts in Neubauer chamber and
differential counts in slices stained by Rosenfelt method. We
obtained 94% of neutrophils in a pool of 10 mice. Neutrophils were
suspended in K2HPO4 buffer containing HTAB and stored at 80 C
until use.
2.7. Oxidative stress tests
2.7.1. ABTS and FRAP assays
The ability of samples to resist oxidative damage was deter-
mined by its free radical scavenging (ABTS [2,20-Azinobis-3-ethyl
benzothiazoline 6-sulfonicacid] assay) and ferric reducing (FRAP
assay) properties. The tests were adapted to a 96-well microplate
Fig. 1. Vinpocetine inhibited lipopolysaccharide (LPS)-induced hyperalgesia and myeloperoxidase activity (MPO). Mice were treated with vinpocetine (3, 10, or 30 mg/kg,
p.o.) or vehicle (saline) 1 h before LPS (200 ng/25 lL) i.pl. injection. Mechanical (Panel A) and thermal hyperalgesia (Panel B) were assessed by electronic von Frey and hot
plate apparatus, respectively. Myeloperoxidase (MPO) activity (Panel C) was determined in plantar paw skin samples collected 5 h after LPS injection. Results are presented as
means ± SEM of 6 mice per group per experiment, and are representative of 2 separated experiments. *P < 0.05 compared with saline group; #P < 0.05 compared with
LPS + vehicle group; and ##P < 0.05 compared with LPS + 10 mg/kg of vinpocetine. One-way ANOVA followed by Tukey’s t test.
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were collected 3 h after i.pl. stimulus with LPS and homogenized
immediately in ice-cold KCl buffer (500 lL, 1.15% w/v). The absor-
bance of ABTS and FRAP assays were measured at 730 and 595 nm
(Multiskan GO Thermo Scientiﬁc), respectively, and the results
were equated against a standard Trolox curve (0.02–20 nmol).
2.7.2. GSH levels
Samples of plantar paw skin were collected and maintained at
80 C for 48 h before the test. The GSH levels in samples were
measured as described previously [43], and the absorbance was
measured at 412 nm (Multiskan GO, Thermo Scientiﬁc). Results
were equated against a standard GSH curve (0.02–20 nmol) and
expressed as nmol of GSH per mg of tissue.
2.7.3. Superoxide anion production
The measurement of superoxide anion production in plantar
paw skin homogenates (10 mg/mL in 1.15% KCl) was performed
using the nitroblue tetrazolium (NBT) assay adapted to a micro-
plate as described previously [44]. The NBT reduction was mea-
sured at 600 nm (Multiskan GO, Thermo Scientiﬁc). The tissue
weight was used for data normalization.
2.7.4. Nitrite production
Samples from plantar paw skin were collected 3 h after LPS
injection, homogenized in 500 lL of saline, and nitrite concentra-
tion was determined by the Griess reaction as an indicator of nitric
oxide production [45]. Brieﬂy, 100 lL of the homogenate was incu-
bated with 100 lL of Griess reagent for 5 min at 25 C, and nitrite
concentration was determined by measuring the optical density at
550 nm (Multiskan GO, Thermo Scientiﬁc) in reference to a stan-
dard curve of NaNO2 solution. Results are expressed as lmol of
nitrite per mg of tissue.
2.7.5. Lipid peroxidation
Lipid peroxidation was measured by the Thiobarbituric Acid
Reactive Substances (TBARS) assay as described previously [43].
Plantar paw skin sampleswere collected 3 h after i.pl. stimuluswith
LPS and homogenized immediately in ice-cold KCl buffer (500 lL,1.15%w/v).Malondialdehyde (MDA) levels, an intermediateproduct
of lipid peroxidation, was determined in samples by the difference
between absorbance at 535 and 572 nm (Multiskan GO, Thermo
Scientiﬁc). Results are reported as nmol of MDA per mg of tissue.
2.8. Total and differential cell counts
Peritoneal cells were harvested with 1.5 mL of PBS 2 h and 6 h
after LPS i.p. injection. Aliquots of 20 lL were mixed with 180 lL
of Turk’s solution, and the total cell counts were performed in
Neubauer chamber. Differential cell counts were performed on
microscope slides using the Panoptic staining kit for histological
analysis (Laborclin, Pinhais, PR, Brazil). The values were expressed
as the total number of cells  104 per cavity. Total and differential
cell counts were both performed under a light microscope (400
magniﬁcation, Olympus Optical Co., Germany).
2.9. Cytokine measurement
Samples from peritoneal exudates were collected by washing
peritoneal cavity with 1.5 mL of PBS containing protease inhibitor
(1 mM phenylmethanesulfonyl ﬂuoride, Sigma Aldrich) 2 and 6 h
after LPS i.p. injection. TNF-a, IL-1b, and IL-33 levels were deter-
mined by an enzyme-linked immunosorbent assay (ELISA) using
eBioscience kits. The results were equated against standard curves
and are expressed as picograms (pg) of each cytokine per cavity.
2.10. Cell culture, luciferase activity and lactate dehydrogenase (LDH)
leakage
The murine macrophage cell line RAW 264.7, stably expressing
luciferase on NF-jB responsive promoter (pNF-jB-Luc) [46], was
routinely cultured in Dulbecco’s modiﬁed Eagle’s medium supple-
mented (10% fetal bovine serum and penicillin–streptomycin) at
37 C in a humidiﬁed atmosphere of 5% CO2. For the luciferase
reporter assay, RAW 264.7 macrophages (3  105 cells/well) were
grown in 24 well plates. After culturing for 24 h, cells were treated
with different drug concentrations and stimulated with
lipopolysaccharide (1 lg/mL). Intracellular contents were
Fig. 2. Vinpocetine reduces LPS-induced oxidative stress in plantar paw skin. Mice were treated with vinpocetine (30 mg/kg, p.o.) or vehicle 1 h before i.pl. stimulus with LPS
(200 ng/25 lL). Plantar paw skin samples were collected 3 h after LPS injection and used to measure the ability to scavenge ABTS free radical (Panel A), ferric reducing ability
potential (FRAP) (Panel B), reduced gluthathione (GSH) levels (panel C), and superoxide anion (Panel D), nitrite (Panel E), and malondialdehyde (MDA) (Panel F) production.
Results are presented as means ± SEM of 6 mice per group per experiment, and are representative of 2 separated experiments. *P < 0.05 compared to saline group, and
#P < 0.05 compared to LPS + vehicle group. One-way ANOVA followed by Tukey’s t test.
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lysates was determined on a luminometer (Victor X5,
PerkinElmer, Waltham, MA) using the Dual Luciferase Reporter
assay system (Promega, Wisconsin, USA). Data are expressed as a
ratio of relative luminescence units (RLU). LDH leakage was mea-
sured in supernatants to determine cytotoxicity using the
Cytotoxicity Detection KitPLUS (Roche Applied Science, Mannheim,
Germany) according to the manufacture’s directions.
2.11. Data analyses
Results are presented as means ± SEM of measurements made
on 6 mice or 4 wells per group per experiment and are representa-
tive of two independent experiments. Two-way ANOVA was used
to compare the groups and doses at all times when the parameters
were measured at different times after the stimulus injection. The
analyzed factors were treatments, time, and time versus treatment
interaction. One-way ANOVA followed by Tukey’s t-test was per-
formed for each time-point. P < 0.05 was considered signiﬁcant.
3. Results
3.1. Vinpocetine reduces LPS-induced hyperalgesia and
myeloperoxidase (MPO) activity
Mice were treated with vinpocetine (3, 10, or 30 mg/kg, p.o.) 1 h
before LPS (200 ng/25 lL) i.pl. injection. Mechanical (Fig. 1A) andthermal (Fig. 1B) hyperalgesia were evaluated at the indicated time
points after LPS injection. Immediately after the last measurement
(5 h), mice were euthanized and plantar paw skin samples were
collected for MPO activity measurement (Fig. 1C), an indicator of
neutrophil recruitment. LPS injection induced mechanical
(Fig. 1A) and thermal (Fig. 1B) hyperalgesia at all evaluated time
points, and also increased MPO activity 5 h after stimulus
(Fig. 1C). No inhibitory effect was observed in mice treated with
vinpocetine at the dose of 3 mg/kg (Fig. 1). On the other hand,
treatment with 10 mg/kg of vinpocetine inhibited LPS-induced
mechanical hyperalgesia at 3 and 5 h (Fig. 1A), and MPO activity
(Fig. 1C), but no effect was observed regarding thermal hyperalge-
sia (Fig. 1B). The dose of 30 mg/kg of vinpocetine reduced up to 53%
of mechanical hyperalgesia at 3 and 5 h (Fig. 1A), and reduced up to
77% of thermal hyperalgesia at all evaluated time points (Fig. 1B).
Moreover, vinpocetine at the dose of 30 mg/kg abolished
LPS-induced increase of MPO activity (Fig. 1C). Thus, the dose of
30 mg/kg of vinpocetine was selected for the next experiments.
3.2. Vinpocetine reduces oxidative stress induced by LPS in plantar
paw skin
Mice were treated with vinpocetine (30 mg/kg, p.o.) 1 h before
i.pl. stimulus with LPS (200 ng/25 lL). Plantar paw skin samples
were collected 3 h after stimulus injection and used to evaluate
the oxidative stress (Fig. 2). LPS injection reduced the levels of
endogenous antioxidants as observed in ABTS free radical
Fig. 3. Vinpocetine inhibited LPS-induced leukocyte migration in the peritoneal
cavity. Mice were treated with vinpocetine (3, 10, or 30 mg/kg, p.o.) or vehicle
(saline) 1 h before i.p. injection of LPS (200 ng/200 lL). Total leukocytes (Panels A
and B), neutrophils (Panels C and D), and mononuclear cells (Panels E and F) were
assessed 2 h and 6 h after LPS injection in peritoneal samples. Results are presented
as means ± SEM of 6 mice per group per experiment, and are representative of 2
separated experiments. *P < 0.05 compared to saline group, and #P < 0.05 compared
to LPS + vehicle group. One-way ANOVA followed by Tukey’s t test.
Fig. 4. Vinpocetine inhibited LPS-induced cytokine production in the peritoneal
cavity. Mice were treated with vinpocetine (3, 10, or 30 mg/kg, p.o.) or vehicle
(saline) 1 h before i.p. injection of LPS (200 ng/200 lL). Peritoneal exudate samples
were collected 2 h (Panels A, C and E) and 6 h (Panels B, D and F) after LPS injection,
and the levels of TNF-a (Panels A and C), IL-1b (Panels B and D) and IL-33 (Panels E
and F) were determined. Results are presented as means ± SEM of 6 mice per group
per experiment, and are representative of 2 separated experiments. *P < 0.05
compared to saline group, and #P < 0.05 compared to LPS + vehicle group. One-way
ANOVA followed by Tukey’s t test.
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assays. These results are in line with the increases in superoxide
anion (Fig. 2D), nitrite (Fig. 2E), and MDA (Fig. 2F) production that
were induced by LPS injection. The treatment with vinpocetine, in
turn, inhibited up to 78% and 80% of LPS-induced superoxide anion
(Fig. 2D) and nitrite (Fig. 2E) production, respectively. The oxida-
tive stress was also inhibited up to 100% by vinpocetine treatment
(Fig 2A–E).3.3. Vinpocetine reduced LPS-induced leukocyte recruitment in the
peritoneal cavity
Mice were treated with vinpocetine (3, 10, or 30 mg/kg, p.o.) 1 h
before i.p. injection of LPS (200 ng/200 lL), and the leukocyte
Fig. 5. Vinpocetine inhibited LPS-induced NF-jB activation and IL-1b, TNF-a and IL-
33 production by macrophages. RAW 264.7 macrophages were treated with
vinpocetine (2.5–7.5 lM) or vehicle (medium) 1 h before stimulus with LPS (1 lg/
mL). Luciferase activity in cell lysates (Panel A), cytokine production (Panels B–D)
and LDH levels (Panel E) in supernatants were determined 6 h after LPS stimulus.
Results are presented as means ± SEM of 4 wells per group per experiment, and are
representative of 2 separated experiments. *P < 0.05 compared to medium group,
and #P < 0.05 compared to LPS + 0 mg/kg group. One-way ANOVA followed by
Tukey’s t test.
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(Fig. 3A, C and E) and 6 h (Fig. 3B, D and F) later. LPS injection
induced signiﬁcant increase of leukocyte recruitment at 2 h
(Fig. 3A) and 6 h (Fig. 3B). All doses of vinpocetine were capable
of reducing LPS-induced leukocyte recruitment at 2 h (Fig. 3A),
but only the doses of 10 and 30 mg/kg of vinpocetine showed efﬁ-
cacy at 6 h (Fig. 3B). At 2 h after LPS injection, all doses of vin-
pocetine were capable of reducing neutrophil (Fig. 3C) and
mononuclear cell (Fig. 3E) recruitment. At 6 h, neutrophil recruit-
ment was reduced by treatment with vinpocetine at doses of 10and 30 mg/kg (Fig. 3D), whilst mononuclear cell recruitment was
reduced only by vinpocetine at the dose of 30 mg/kg (Fig. 3F).
3.4. Vinpocetine inhibits LPS-induced cytokine production in the
peritoneal cavity
Mice were treated with vinpocetine (3, 10 or 30 mg/kg, p.o.) 1 h
before i.p. injection of LPS (200 ng/200 lL). The levels of TNF-a,
IL-1b, and IL-33 were measured 2 and 6 h after LPS injection. LPS
injection induced TNF-a, IL-1b, and IL-33 production at 2 h
(Fig. 4A, C, and E, respectively) and 6 h (Fig. 4B, D, and F, respec-
tively). The treatment with vinpocetine at the dose of 30 mg/kg
inhibited TNF-a, IL-1b, and IL-33 production at 2 h
(Fig. 4A, C, and E) by up to 88%, 79% and 76%, respectively, and at
6 h (Fig. 4B, D, and F) by up to 100%, 91% and 100%, respectively.
At the dose of 10 mg/kg, vinpocetine also reduced the production
of these cytokines, except by IL-1b at 6 h (Fig. 4D), while the treat-
ment with vinpocetine at the dose of 3 mg/kg reduced TNF-a levels
at 2 h (Fig. 4A) and 6 h (Fig. 4B), and reduced IL-33 levels at 6 h
(Fig. 4F).
3.5. Vinpocetine inhibits LPS-induced NF-jB activation and cytokine
production in RAW 264.7 macrophages
RAW 264.7 macrophages (5  105 cells/well), stably expressing
luciferase on NF-jB responsive promoter, were pre-treated with
vinpocetine (2.5–7.5 lM) 1 h before LPS treatment (1 lg/mL).
NF-jB activation (luciferase activity in cell lysates) and cytokine
release (ELISA in supernatants) were measured 6 h after LPS treat-
ment. The pre-treatment with vinpocetine at the concentration of
7.5 lM reduced LPS-induced NF-jB activation (Fig. 5A) by 87%,
and the release of TNF-a (Fig. 5B), IL-1b (Fig. 5C), and IL-33
(Fig. 5D) by 65%, 72%, and 45%, respectively. Neither LPS nor vin-
pocetine were cytotoxic as determined by LDH assay (Fig. 5E).4. Discussion
As the most abundant constituent of gram-negative bacterial
cell wall, LPS is released in large amounts after lysis of bacteria
induced either by endogenous (e.g. complement, lysozyme) and
exogenous (bacteriolytic antibiotics) molecules. LPS plays a major
role in the pathophysiology of infectious diseases due to its high
pro-inﬂammatory activity [4,6,7,47]. Macrophages are
tissue-resident cells from innate immune system capable of recog-
nizing pathogens via pattern recognition receptors (PRR) and are
crucial to protect the host against bacterial infections. TLR4 is a
PRR responsible for recognizing LPS, and consequent activation of
macrophages triggers inﬂammation through the production and
release of pro-inﬂammatory cytokines such as TNF-a, IL-1b, and
IL-33 [7].
The anti-inﬂammatory activity of vinpocetine was recently
demonstrated to be dependent on inhibition of NF-jB pathway
in TNF-a-stimulated macrophages [32]. In line with this previous
work, our results show that vinpocetine inhibited LPS-induced
NF-jB activation and TNF-a, IL-1b, and IL-33 production by macro-
phages. When these cytokines activate endothelial cells, they
up-regulate the expression of adhesion molecules promoting neu-
trophil recruitment to tissue [48–50]. Importantly, neutrophils are
the major sources of myeloperoxidase, a bacteriolytic enzyme that
increases LPS release during gram-negative bacteria infection [5].
Herein, we used in vivo approaches to show that vinpocetine treat-
ment reduces neutrophil recruitment (into the peritoneal cavity)
and the activity of myeloperoxidase (in plantar paw skin) induced
by LPS in mice. Taking into account the similar temporal pattern of
inhibition between leukocyte recruitment and cytokine production
Fig. 6. Proposed targets of vinpocetine in LPS-induced inﬂammation, oxidative stress and pain. LPS activates TLR4 on resident inﬂammatory cells, which leads to activation of
NF-jB and consequent production of inﬂammatory cytokines (TNFa, IL-1b, IL-33), superoxide anion (O2), nitric oxide (NO) and lipid peroxidation (LPO), and diminished
levels of reduced glutathione (GSH), reduced ability to reduce iron (FRAP) and to scavenge ABTS free radicals [6–8]. The inﬂammatory molecules are released and induce
inﬂammation (leukocyte recruitment and myeloperoxidase activity) and pain [15–24].
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phages in vitro, we suggest that vinpocetine can target tissue resi-
dent macrophages activation reducing LPS-induced inﬂammation
and pain. Consistent with our results, vinpocetine inhibits neu-
trophil recruitment and expression of TNF-a, IL-1b, and MIP-2 in
a mouse model of lung inﬂammation induced by LPS [32].
Neutrophils produce large amounts of superoxide and peroxyni-
trite anion (formed from the reaction of superoxide anionwith nitric
oxide) and play a central role in oxidative stress and tissue damage
during inﬂammation. Vinpocetine inhibited oxidative stress as
observed by enhanced ability to scavenge ABTS radical, ferric reduc-
ing ability, prevention of GSH depletion, reduced superoxide anion
and nitric oxide production, and lipid peroxidation. The oxidative
stress sustains inﬂammatory response by mechanisms including
NF-jB activation and the production of IL-1b and TNF-a.
Additionally, these cytokines contribute to increase tissue damage
by extending the survival of neutrophils [51]. Considering themech-
anisms described above (Fig. 6), we conclude that vinpocetine exhi-
bits a strong anti-inﬂammatory effect and represents a safe
approach [21,52] to control inﬂammation-related disorders, includ-
ing mononuclear/neutrophil recruitment and inﬂammatory pain.
LPS induces acute hyperalgesia in mice in a MyD88 (myeloid
differentiation primary response 88)-dependent and
TRIF-independent manner [15], suggesting the role of the NF-jB
pathway and pro-inﬂammatory cytokines in the nociceptive sensi-
tization process. Furthermore, vinpocetine inhibits LPS-induced
lung inﬂammation and TNF-a-induced cellular activation by tar-
geting IKK independently of PDE-1 [32]. TNF-a, IL-1b, and IL-33
are pro-hyperalgesic cytokines due to their capacity of acting on
nociceptive neurons to induce its depolarization and/or to induce
further production of hyperalgesic molecules capable of activating
nociceptive neurons [11,14,53–55]. Superoxide and peroxynitrite
also sensitize nociceptive ﬁbers and induce pain [9,56–60]. Thus,
it is reasonable to consider that vinpocetine inhibited
LPS-induced inﬂammatory pain by reducing the production of such
hyperalgesic mediators. It has been described that even when low
doses of LPS (0.4 ng/kg) reaches the blood, it increases systemic
immune activation and the pain sensitivity [61], corroborating
the idea that small peripheral immune activation is sufﬁcient to
modulate pain thresholds [62]. Moreover, bacterial components
(e.g. N-formylated peptides and LPS) activate nociceptors in a cal-
cium ﬂux-dependent manner [63,64]. Vinpocetine also actsdirectly on neurons to block sodium currents and the resulting
increase of intracellular calcium levels [65–68], suggesting that
these activities may represent contributing mechanisms by which
this compound inhibits LPS-induced neuronal activation.
Additionally, vinpocetine inhibits the PDE-1 activation and thus
increases cGMP levels, which is a mechanism of action of anal-
gesics and nitric oxide donors [69–72]. On the other hand, the
PDE-1 inhibition by vinpocetine also leads to increases in cAMP
levels that, in turn, induce protein kinase A (PKA) and PKCe activity
in neurons, a mechanism that could increase pain sensation
[73,74]. Taking into account the role of nociceptor sensory neuron
activation in neurogenic inﬂammation [64], the effect of vin-
pocetine in this context needs to be further investigated.5. Conclusion
Pain is one of the most prominent complains of patients with
infectious diseases, and hyperalgesic cytokines play an important
role in this condition. Macrophages and neutrophils are the major
sources of these endogenous hyperalgesic mediators. We found
that vinpocetine inhibited LPS-induced NF-jB activation and cyto-
kine production (TNF-a, IL-1b, and IL-33) in macrophages in vitro,
highlighting its anti-inﬂammatory activity. Similar effects were
observed in vivo, where this compound also reduced the produc-
tion of all evaluated cytokines after LPS intraperitoneal injection.
The recruitment of neutrophils and monocytes to the peritoneal
cavity were also inhibited, which lined up well with the inhibition
of superoxide anion and nitric oxide production, as well as the
resulting oxidative stress (reduction in antioxidant capacity, deple-
tion of GSH, and induction of MDA) in the plantar paw skin (Fig. 6).
The present study did not address the direct acting effects of vin-
pocetine on nociceptors or its effects on central nervous system,
which also represent an important analgesic mechanism of action
and were investigated elsewhere [66,75]. Finally, we suggest that
vinpocetine, which is widely used to treat cognitive disorders, also
represents a promising and safe approach to treat inﬂammatory
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